Fundraising Fox
Alume Biosciences
La Jolla, US · Founded 2017 · Delaware corporation · 17 employees on LinkedIn · 1 known investors
Find your way into Alume Biosciences
Sign up to see every warm intro you have to Alume Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alume Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Alume Biosciences develops nerve illumination technology for surgery, including bevonescein (ALM-488), an injectable peptide that makes nerves glow to help surgeons identify and preserve them during procedures such as head-and-neck and prostate surgery. The drug candidate is in Phase 3 clinical trials, with a planned FDA New Drug Application submission in 2026.
Founders & leadership
Alume Biosciences was founded in 2017 by Quyen Nguyen and Roger Tsien.
QN
Quyen NguyenFounder and CEOQuyen Nguyen is a Professor of Otolaryngology – Head and Neck Surgery at UC San Diego and Co-founder of Alume Biosciences, which develops fluorescent nerve visualization technology for surgery. He has over two decades of experience in healthcare, translational research, and surgical care.
RT
Roger TsienCo-founder
Board
KK
Kim KamdarBoard director
DB
JM
Jean-Pierre MillonBoard director
MM
Magda MarquetBoard director
Investors · 1
BioBritlisted by BioBritLa Jolla
How we know: a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements$35.5M disclosed across 6 of 7 rounds · 2019–2026
- Undisclosed amountSeries AMay 2020Source ↗
▶$2.2MraisedMay 2026 · 4 investors · BiotechnologyRule 506(b)
▶$2.2MraisedMay 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kim KamdarDirector
- Jean-Pierre MillonDirector
- Kaveri ParkerExecutive Officer
- Brett BermanExecutive Officer, Director
- Dan BradburyDirector
- James SchmidtExecutive Officer
- Quyen NguyenExecutive Officer, Director
- Magda MarquetDirector
- Offering amount
- $8M
- Amount sold
- $2.2M
- Minimum investment
- $50K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.9MraisedFeb 2026 · 92 investors · BiotechnologyRule 506(b)
▶$6.9MraisedFeb 2026 · 92 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kim KamdarDirector
- Kaveri ParkerExecutive Officer
- Jean-Pierre MillonDirector
- Brett BermanExecutive Officer, Director
- James SchmidtExecutive Officer
- Dan BradburyDirector
- Quyen NguyenExecutive Officer, Director
- Magda MarquetDirector
- Offering amount
- $23.5M
- Amount sold
- $6.9M
- Minimum investment
- $25K
- Sales commissions
- $662.8K
- Placement agents
- PHX Financial Inc.
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.8MraisedJan 2023 · 43 investors · BiotechnologyRule 506(b)
▶$12.8MraisedJan 2023 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kim KamdarDirector
- Jean-Pierre MillonDirector
- Magda MarquetDirector
- James SchmidtExecutive Officer
- Quyen T. NguyenExecutive Officer, Director
- Dan BradburyDirector
- Brett BermanExecutive Officer, Director
- Offering amount
- $45M
- Amount sold
- $12.8M
- Proceeds to insiders
- $153.6K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedSep 2022 · 26 investors · BiotechnologyRule 506(b)
▶$4MraisedSep 2022 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Magda MarquetDirector
- Quyen T. NguyenExecutive Officer, Director
- Jean-Pierre MillonDirector
- Dan BradburyDirector
- Kim KamdarDirector
- James SchmidtExecutive Officer
- Brett BermanExecutive Officer, Director
- Offering amount
- $5.2M
- Amount sold
- $4M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedAug 2020 · 34 investors · BiotechnologyRule 506(b)
▶$4MraisedAug 2020 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kim KamdarDirector
- Magda MarquetDirector
- Brett BermanExecutive Officer, Director
- James SchmidtExecutive Officer
- Dan BradburyDirector
- Quyen T NguyenExecutive Officer, Director
- Jean-Pierre MillionDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$5.8MraisedJul 2019 · 40 investors · BiotechnologyRule 506(b)
▶$5.8MraisedJul 2019 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Quyen T NguyenExecutive Officer, Director
- James SchmidtExecutive Officer
- Brett BermanExecutive Officer
- Offering amount
- $8.6M
- Amount sold
- $5.8M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
LumenLumen develops orally delivered antibody drugs using engineered spirulina, a patented biologic platform that reduces manufacturing costs and timelines compared to conventional biologics. The company serves biopharma customers seeking alternatives to traditional drug manufacturing.
AlumisAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Mirum PharmaceuticalsMirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases. It operates in the U.S. and Europe, engaging with healthcare professionals, patients, and payers within applicable regulatory frameworks.
Companies working in the same space as Alume Biosciences.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $937.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $3.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Alume Biosciences do?
- Alume Biosciences develops nerve illumination technology for surgery, including bevonescein (ALM-488), an injectable peptide that makes nerves glow to help surgeons identify and preserve them during procedures such as head-and-neck and prostate surgery. The drug candidate is in Phase 3 clinical trials, with a planned FDA New Drug Application submission in 2026.
- Who founded Alume Biosciences?
- Alume Biosciences was founded by Quyen Nguyen, Roger Tsien in 2017.
- Who are Alume Biosciences's investors?
- Alume Biosciences's investors include BioBrit.
- How much funding has Alume Biosciences raised?
- Alume Biosciences has disclosed $35.5M raised across 6 of its 7 known rounds.
- Where is Alume Biosciences headquartered?
- Alume Biosciences is headquartered in La Jolla, US.